Tcr2 Therapeutics Stock Current Valuation
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
Valuation analysis of Tcr2 Therapeutics helps investors to measure Tcr2 Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Tcr2 Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Tcr2 Therapeutics is based on 3 months time horizon. Increasing Tcr2 Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tcr2 stock is determined by what a typical buyer is willing to pay for full or partial control of Tcr2 Therapeutics. Since Tcr2 Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tcr2 Stock. However, Tcr2 Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.48 | Real 1.35 | Hype 1.48 | Naive 1.35 |
The intrinsic value of Tcr2 Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tcr2 Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tcr2 Therapeutics helps investors to forecast how Tcr2 stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tcr2 Therapeutics more accurately as focusing exclusively on Tcr2 Therapeutics' fundamentals will not take into account other important factors: Tcr2 Therapeutics Company Current Valuation Analysis
Tcr2 Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Tcr2 Therapeutics Current Valuation | (73.69 M) |
Most of Tcr2 Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tcr2 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Tcr2 Therapeutics has a Current Valuation of (73.69 Million). This is 100.51% lower than that of the Biotechnology sector and 101.59% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.44% higher than that of the company.
Tcr2 Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tcr2 Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tcr2 Therapeutics could also be used in its relative valuation, which is a method of valuing Tcr2 Therapeutics by comparing valuation metrics of similar companies.Tcr2 Therapeutics is currently under evaluation in current valuation category among its peers.
Tcr2 Fundamentals
| Return On Equity | -0.91 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | (73.69 M) | |||
| Shares Outstanding | 39.26 M | |||
| Shares Owned By Insiders | 1.50 % | |||
| Shares Owned By Institutions | 54.31 % | |||
| Number Of Shares Shorted | 360.89 K | |||
| Price To Book | 0.22 X | |||
| EBITDA | (89.62 M) | |||
| Net Income | (151.82 M) | |||
| Cash And Equivalents | 175.99 M | |||
| Cash Per Share | 4.55 X | |||
| Total Debt | 58.23 M | |||
| Debt To Equity | 0.29 % | |||
| Current Ratio | 5.02 X | |||
| Book Value Per Share | 2.58 X | |||
| Cash Flow From Operations | (101.46 M) | |||
| Short Ratio | 1.29 X | |||
| Earnings Per Share | (4.20) X | |||
| Target Price | 6.43 | |||
| Number Of Employees | 58 | |||
| Beta | 1.93 | |||
| Market Capitalization | 58.11 M | |||
| Total Asset | 208.24 M | |||
| Retained Earnings | (501.34 M) | |||
| Working Capital | 113.56 M | |||
| Z Score | -3.54 | |||
| Net Asset | 208.24 M |
About Tcr2 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tcr2 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tcr2 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tcr2 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Tcr2 Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Tcr2 Stock
| 0.86 | EC | Ecopetrol SA ADR | PairCorr |
| 0.68 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.67 | SHG | Shinhan Financial | PairCorr |
| 0.59 | WF | Woori Financial Group | PairCorr |
| 0.56 | TLK | Telkom Indonesia Tbk | PairCorr |
The ability to find closely correlated positions to Tcr2 Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tcr2 Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tcr2 Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tcr2 Therapeutics to buy it.
The correlation of Tcr2 Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tcr2 Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tcr2 Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tcr2 Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |